Newer agents in antiplatelet therapy: a review

Area of Science:

• Cardiovascular Research
• Pharmacology
• Hematology

Background:

• Antiplatelet therapy is crucial for preventing platelet activation in cardiovascular diseases like myocardial infarction, ischemia, and stroke.
• Aspirin is the current gold standard, but faces limitations in safety, efficacy, and tolerability.
• Existing antiplatelet drugs have shown issues with bleeding risk, recurrent thrombosis, and variable pharmacokinetic/pharmacodynamic profiles.

Purpose of the Study:

• To review advancements in antiplatelet therapies.
• To highlight the limitations of current antiplatelet drugs.
• To discuss the development of novel antiplatelet agents targeting specific platelet pathways.

Main Methods:

• Literature review of antiplatelet therapy research.
• Analysis of pharmacokinetic and pharmacodynamic profiles of antiplatelet agents.
• Identification of molecular targets for new antiplatelet drug development.

Main Results:

• Despite progress, aspirin remains the primary treatment for aberrant platelet activation.
• Development of next-generation antiplatelet therapies is hindered by safety and efficacy concerns.
• Numerous potential antiplatelet drugs targeting platelet enzymes, receptors, and glycoproteins are under investigation.

Conclusions:

• There is a continued need for superior antiplatelet therapies beyond aspirin.
• New agents aim to offer improved pharmacodynamic profiles and reduced side effects.
• Ongoing research seeks to validate novel antiplatelet approaches for better patient outcomes.